This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
by Kinjel Shah
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.
Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection
by Zacks Equity Research
Incyte (INCY) plans to work with the FDA for evaluating Jakafi in patients with COVID-19-associated cytokine storm.
Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss
by Zacks Equity Research
The FDA grants breakthrough therapy status to Eli Lilly's (LLY) oral JAK inhibitor, Olumiant (baricitinib) for potential treatment of alopecia areata, an autoimmune disorder leading to hair loss.
Incyte (INCY) Down 5.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
by Zacks Equity Research
The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals
Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio
by Zacks Equity Research
The biotech sector was in focus with pipeline updates from a few small biotech companies.
Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates
by Zacks Equity Research
It was a low-key week for the biotech sector with updates from just a few small biotech companies.
Stock Market News for Feb 14, 2020
by Zacks Equity Research
U.S. stocks slid Thursday following a massive jump in coronavirus cases.
Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales
by Zacks Equity Research
Incyte (INCY) beats on earnings & sales in the fourth quarter on strong Jakafi growth.
Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.
Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study
by Zacks Equity Research
Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.
Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal
by Zacks Equity Research
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data
by Zacks Equity Research
It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.
Incyte (INCY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Incyte (INCY) closed at $76.46 in the latest trading session, marking a +0.51% move from the prior day.
Lilly's Olumiant Meets Primary Goal in Dermatitis Study
by Zacks Equity Research
Eli Lilly (LLY) and partner Incyte's Olumiant meets primary endpoint in atopic dermatitis in a late-stage study.
Incyte (INCY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Incyte (INCY) closed at $76.53 in the latest trading session, marking a -0.79% move from the prior day.
Incyte's Application for Pemigatinib Gets EMA's Validation
by Zacks Equity Research
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data
by Zacks Equity Research
A low-key week for the biotech sector, with a few pipeline and regulatory updates.
Company News For Jan 6, 2020
by Zacks Equity Research
Companies In The News Are: CANF, LW, INCY, NOVN
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
by Zacks Equity Research
Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.
Incyte (INCY) Stock Moves -0.44%: What You Should Know
by Zacks Equity Research
In the latest trading session, Incyte (INCY) closed at $88.39, marking a -0.44% move from the previous day.
Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.
Has Incyte (INCY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (INCY) Outperforming Other Medical Stocks This Year?